Literature DB >> 18225579

Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.

H Arzu Ergen1, Uzay Gormus, Fehmi Narter, Umit Zeybek, Sibel Bulgurcuoglu, Turgay Isbir.   

Abstract

BACKGROUND: NAD(P)H:quinone oxidoreductase 1 (NQO1) is a part of the antioxidant defense system. NQO1 protects cells from oxidative stress by maintaining antioxidant forms of ubiquinone and vitamin E and this enzymatic activity can be sufficient to protect against carcinogenesis. Oxidative stress may contribute to carcinogenesis as an important risk factor. This study aimed to investigate the relationship between prostate cancer and NQO1 C609T polymorphism in a Turkish population. PATIENTS AND METHODS: Forty-five patients with prostate cancer and fifty healthy controls were included in this study. Gene polymorphism was determined by a restricted fragment length polymorphism-polymerase chain reaction (PCR-RFLP) method.
RESULTS: The NQO1 TT genotype was demonstrated to be increased in patients, there were no significant differences between distributions of NQO1 C609T genotypes in the study groups. Serum PSA and alkaline phosphatase levels were elevated in patients carrying T alleles (TT > CT > CC). There were no correlations between tumor size, node classification, metastasis or stage and NQO1 genotypes.
CONCLUSION: The results of our study of Turkish prostate cancer patients suggests that mutation of the NQO1 gene may effect the serum PSA and alkaline phosphatase levels. However there were no differences between the NQO1 genotypes in the study groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18225579

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India.

Authors:  Raju K Mandal; Kamran Nissar; Rama D Mittal
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

Review 2.  Association between NQO1 C609T polymorphism and prostate cancer risk.

Authors:  Zihan Sun; Yuling Cui; Jing Pei; Zhiqiang Fan
Journal:  Tumour Biol       Date:  2014-05-17

3.  DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Authors:  Daniela Kurfurstova; Jirina Bartkova; Radek Vrtel; Alena Mickova; Alena Burdova; Dusana Majera; Martin Mistrik; Milan Kral; Frederic R Santer; Jan Bouchal; Jiri Bartek
Journal:  Mol Oncol       Date:  2016-03-03       Impact factor: 6.603

4.  Loss of NADPH quinone oxidoreductase in the prostate and enhanced serum levels of cytokine-induced neutrophil chemoattractant 2alpha in hormone-stimulated noble rats: potential role in prostatic intraepithelial neoplasia development.

Authors:  Rita Ghosh; John Schoolfield; I-Tien Yeh; Maxwell L Smith; Stephen D Hursting; Daniel C Chan; M Scott Lucia; Addanki P Kumar
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

5.  Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.

Authors:  Imen Hemissi; Haroun Ayed; Zeineb Naimi; Khedija Meddeb; Mouna Ayadi; Skander Zouari; Selim Zaghbib; Emna Talbi; Mohamed Chebil; Slah Ouerhani
Journal:  Mol Genet Genomic Med       Date:  2021-09-22       Impact factor: 2.183

6.  NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in Caucasians.

Authors:  Christine G Stoehr; Elke Nolte; Sven Wach; Wolf F Wieland; Ferdinand Hofstaedter; Arndt Hartmann; Robert Stoehr
Journal:  Int J Mol Sci       Date:  2012-07-26       Impact factor: 6.208

7.  The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis.

Authors:  B Lajin; A Alachkar
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

8.  Effect of NQO1 C609T polymorphism on prostate cancer risk: a meta-analysis.

Authors:  Qi Zhang; Min Zheng; Xiao-Long Qi; Feng Liu; Zu-Jie Mao; Da-Hong Zhang
Journal:  Onco Targets Ther       Date:  2014-06-05       Impact factor: 4.147

9.  Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma.

Authors:  Kecheng Lei; Xiaoxia Gu; Alvaro G Alvarado; Yuhong Du; Shilin Luo; Eun Hee Ahn; Seong Su Kang; Bing Ji; Xia Liu; Hui Mao; Haian Fu; Harley I Kornblum; Lingjing Jin; Hua Li; Keqiang Ye
Journal:  J Hematol Oncol       Date:  2020-10-21       Impact factor: 23.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.